Article ID Journal Published Year Pages File Type
2500675 Farmacia Hospitalaria 2006 9 Pages PDF
Abstract
BIA models can be useful for the inclusion or reassessment of drugs in formularies. In this case, the treatment with pegIFN alfa-2b + RIB (in comparison with pegIFN alfa-2a + RIB) is an efficient strategy although it depends on acquisition prices, and so, it would be rarely useful in other centres. In our hospital it would produce a budgetary saving that would range from 71,358 to 80,986 euros, which would represent a 7,5-8,6% of the total cost of the pharmacological treatment of the CHC
Related Topics
Health Sciences Pharmacology, Toxicology and Pharmaceutical Science Pharmaceutical Science
Authors
, , , , ,